Aprea Therapeutics Stock Revenue
| APRE Stock | USD 0.85 0 0.40% |
Fundamental analysis of Aprea Therapeutics allows traders to better anticipate movements in Aprea Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 1.7 M | 1.8 M |
Aprea | Revenue | Build AI portfolio with Aprea Stock |
Aprea Therapeutics Company Revenue Analysis
Aprea Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Aprea Therapeutics Revenue | 1.5 M |
Most of Aprea Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aprea Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Aprea
Projected quarterly revenue analysis of Aprea Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Aprea Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Aprea Therapeutics' stock price.
Aprea Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Aprea Therapeutics is extremely important. It helps to project a fair market value of Aprea Stock properly, considering its historical fundamentals such as Revenue. Since Aprea Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aprea Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aprea Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Aprea Therapeutics reported 1.5 M of revenue. This is 99.98% lower than that of the Biotechnology sector and 99.8% lower than that of the Health Care industry. The revenue for all United States stocks is 99.98% higher than that of the company.
Aprea Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aprea Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aprea Therapeutics could also be used in its relative valuation, which is a method of valuing Aprea Therapeutics by comparing valuation metrics of similar companies.Aprea Therapeutics is currently under evaluation in revenue category among its peers.
Aprea Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Aprea Therapeutics from analyzing Aprea Therapeutics' financial statements. These drivers represent accounts that assess Aprea Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Aprea Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 61.1M | 548.5K | 17.0M | 18.1M | 20.8M | 19.8M | |
| Enterprise Value | 8.2M | (28.2M) | (4.6M) | (4.7M) | (5.4M) | (5.2M) |
Aprea Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Aprea Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aprea Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aprea Therapeutics' value.| Shares | Dimensional Fund Advisors, Inc. | 2025-06-30 | 14.5 K | Hightower Advisors, Llc | 2025-06-30 | 13.9 K | Blackrock Inc | 2025-06-30 | 8.5 K | Bank Of America Corp | 2025-06-30 | 4.9 K | Tower Research Capital Llc | 2025-06-30 | 3 K | Mb, Levis & Associates, Llc | 2025-06-30 | 806 | Group One Trading, Lp | 2025-06-30 | 577 | Fmr Inc | 2025-06-30 | 501 | Advisor Group Holdings, Inc. | 2025-06-30 | 400 | Aigh Capital Management, Llc | 2025-06-30 | 539.3 K | Sio Capital Management, Llc | 2025-06-30 | 279.4 K |
Aprea Fundamentals
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | (7.75 M) | ||||
| Shares Outstanding | 6.99 M | ||||
| Shares Owned By Insiders | 21.65 % | ||||
| Shares Owned By Institutions | 25.68 % | ||||
| Number Of Shares Shorted | 34.58 K | ||||
| Price To Earning | (9.54) X | ||||
| Price To Book | 0.55 X | ||||
| Price To Sales | 12.22 X | ||||
| Revenue | 1.5 M | ||||
| Gross Profit | (7.91 M) | ||||
| EBITDA | (14.3 M) | ||||
| Net Income | (12.96 M) | ||||
| Cash And Equivalents | 39.06 M | ||||
| Cash Per Share | 1.67 X | ||||
| Total Debt | 4.67 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.45 X | ||||
| Book Value Per Share | 1.82 X | ||||
| Cash Flow From Operations | (13.56 M) | ||||
| Short Ratio | 0.48 X | ||||
| Earnings Per Share | (2.12) X | ||||
| Target Price | 7.0 | ||||
| Beta | 1.57 | ||||
| Market Capitalization | 5.97 M | ||||
| Total Asset | 23.98 M | ||||
| Retained Earnings | (321.04 M) | ||||
| Working Capital | 20.22 M | ||||
| Current Asset | 39.28 M | ||||
| Current Liabilities | 5.96 M | ||||
| Net Asset | 23.98 M |
About Aprea Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aprea Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aprea Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aprea Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Check out Aprea Therapeutics Piotroski F Score and Aprea Therapeutics Altman Z Score analysis. For information on how to trade Aprea Stock refer to our How to Trade Aprea Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aprea Therapeutics. If investors know Aprea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aprea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.12) | Revenue Per Share | Quarterly Revenue Growth (0.99) | Return On Assets | Return On Equity |
The market value of Aprea Therapeutics is measured differently than its book value, which is the value of Aprea that is recorded on the company's balance sheet. Investors also form their own opinion of Aprea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aprea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aprea Therapeutics' market value can be influenced by many factors that don't directly affect Aprea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aprea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aprea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aprea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.